The OligoGpivotalCF trial is about to start recruiting. On 6th May 2020 the first site was initiated in Wels, Austria and more site initiation visits are planned for the coming months. Pending the normalization of the Covid-19 pandemic, the trial will open for patients at several sites in Europe soon. If you want to know […]
We have now received regulatory approvals from Austria, UK, Germany and Ireland, and ethics approvals from Austria and UK. Ethics approvals from Germany and Ireland are expected to follow soon in order for us to proceed with the OligoGpivotalCF clinical study. However, due to the current situation with COVID-19, we have decided to postpone site […]
An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.
About the project
OligoG-pivotal-CF is a multinational clinical project to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase 2b clinical trial for the treatment of cystic fibrosis (CF). The project is funded by the H2020-SC1-2017-Two-Stage-RTD, topic SC1-PM-08-2017, and represents a new therapy for the rare disease cystic fibrosis (CF). The study drug OligoG CF-5/20 (OligoG) has received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, both for the treatment of cystic fibrosis.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme part “Health, demographic change and well-being” (call H2020-SC1-2016-2017) under grant agreement No 755234.